The American Society of Clinical Oncology (ASCO) and Conexiant have announced the launch of ASCO AI in Oncology, a dedicated digital platform created to help oncology professionals understand and apply artificial intelligence in cancer care. The initiative represents a new phase in how clinicians, researchers, and health systems can access credible AI-related information at a time when innovation is moving faster than many institutions can comfortably evaluate or implement it.
The launch also marks a significant milestone in the partnership between ASCO and Conexiant. It is their second major collaboration following the success of The ASCO Post, established in 2010. That publication became a familiar reference point for oncology news and commentary; ASCO AI in Oncology now extends the collaboration into one of the most urgent and complex frontiers in modern medicine.
Why this Platform, and Why Now
Artificial intelligence has shifted from being a distant promise to a practical force already influencing oncology workflows. AI-enabled approaches are increasingly present in diagnostic imaging, pathology, risk assessment, and treatment decision support. Yet alongside that progress has come a familiar problem: volume without clarity. Clinicians are faced with a flood of tools, claims,s, and studies, often presented with uneven levels of evidence or with hype that can blur what is truly ready for clinical adoption.
ASCO AI in Oncology is designed to meet that reality head-on. Its central purpose is not to promote AI as a trend, but to support professionals with reliable research, interpretive context, and current information that can be used to make informed decisions. The platform positions itself as a learning space where oncology teams can stay prepared as AI becomes more embedded in routine care, while also remaining critical about its limitations and responsible deployment.
A Structure Built Around Credibility and Clinical Value
At the heart of the platform is a clear editorial framework intended to balance scientific rigor with practical relevance. ASCO AI in Oncology is built around trusted, expert-led perspectives from authoritative sources, with an emphasis on clinical usefulness rather than abstract technical discussion. It also focuses on education that translates AI capabilities into real-world application, exploring how emerging tools may improve diagnostic accuracy, streamline workflows, and contribute to more personalized treatment pathways. Just as importantly, the platform emphasizes professional community, aiming to connect oncology clinicians and researchers across disciplines and institutions so they can share implementation experiences and learn from one another’s successes and setbacks.
Beyond deep clinical analysis, ASCO AI in Oncology will include practitioner-submitted commentary and interactive programs geared toward professional development. The intent is to offer not only information, but also a space for conversation and skill-building—an acknowledgment that AI’s impact in oncology will be shaped as much by how it is used in clinics as by how it is developed in labs.
Cutting Through “AI noise” in Oncology
ASCO’s leadership has been direct about the challenge the platform is trying to solve. ASCO CEO Clifford Hudis, MD, FACP, FASCO, highlighted that AI is evolving at a remarkable pace, but that the “noise” surrounding AI can be distracting and confusing for clinicians who simply want to know what is credible, what is practical, and what will benefit patients. He emphasized that delivering insights from trusted experts, and translating those insights into usable guidance, can help clinicians focus on what matters most: patient outcomes.
That message lands in a climate where AI discussions often swing between extremes—either uncritical enthusiasm or outright skepticism. A platform that prioritizes expert interpretation and clinical relevance signals a more mature stance: AI is neither a cure-all nor a threat to be dismissed, but a set of tools that demand careful validation and thoughtful integration.
A Broader Step in ASCO’s AI Strategy
The collaboration with Conexiant reflects ASCO’s larger intention to harness AI responsibly in ways that support oncology professionals and advance cancer care. While the platform is educational in nature, its existence also carries a strategic implication. It suggests that the oncology community is moving toward shared standards of understanding and evaluation—an approach that could prove increasingly important as AI systems are incorporated into diagnosis, treatment planning, and ongoing patient management.
For ASCO, founded in 1964 and representing more than 50,000 oncology professionals worldwide, the launch aligns with its long-standing mission that knowledge conquers cancer. In the context of AI, “knowledge” now includes not only clinical evidence, but also the ability to interpret algorithmic tools, recognize limitations, and apply innovations ethically and effectively.
A Global Digital Destination
With ASCO AI in Oncology, ASCO and Conexiant are positioning the platform as a central, trusted destination for oncology professionals worldwide who are trying to keep pace with AI’s rapid evolution. In a field where the stakes are measured in real patient outcomes, the need for reliable guidance is not optional. This launch is, at its core, an effort to provide that guidance—through expertise, education, and community at the moment it is most needed.
More posts about ASCO on OncoDaily
Written by Nare Hovhannisyan, MD